RxDoctor Payments Data

Maxim Polansky, MD

MOHS-Micrographic Surgery · Chicago, ILNPI 1275913006

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,550, more than ten times the $123 reported in 2020.

$3,678in general payments, 2019–2025

Across 157 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$702
  • Johnson & Johnson$329
  • Regeneron Healthcare Solutions, Inc.$318
  • Novartis$317
  • Arcutis Biotherapeutics, Inc.$254
  • Sanofi$248
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,57897%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,678 in reported general payments places this provider in the 65th percentile of 40 mohs-micrographic surgery providers in Illinois.

See all mohs-micrographic surgery providers in Illinois

Medicare billing

Part B allowed, 2024
$1,519,418
Medicare patients
1,403
Services billed
7,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab18$68,713
Fluorouracil76$5,525
Gentamicin Sulfate102$3,546
Clobetasol Propionate50$3,144
Doxycycline Hyclate720$2,508
Cephalexin625$1,748
Mupirocin205$1,275
Triamcinolone Acetonide109$1,238
Ketoconazole67$928
Hydrocortisone83$514
Nystatin20$344
ValacyclovirValacyclovir Hcl17$193
Ammonium Lactate24$187
Levofloxacin18$63
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$40

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →